Literature DB >> 29230669

P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma.

Wei Dong1,2, Jianhua Li3, Qian Liu1, Chunhui Liu1, Chuzhong Li1, Guidong Song1, Haibo Zhu1, Hua Gao1, Yazhuo Zhang4.   

Abstract

Cell cycle control can prevent excessive proliferative response in the pituitary homeostasis. Cyclin dependent kinases (Cdks) are modulated by cyclins or Cdk inhibitors, such as p21 and p27, which can regulate cell cycle progression from the G1 to S phases. This study was conducted to evaluate the levels and the promoter region methylation status of p21 and p27 in prolactinomas (PRL) and analyze their association with clinicopathologic features. We found high-p21 level cases were featured by 5/23 and H-scores 142.3 ± 23.7 in invasive-PRL specimens, and 19/25 and 221.3 ± 45.4 in non-invasive specimens (x2 = 14.11, p = 0.000), while high-p27 level cases were featured by 6/23 and H-scores 129.8 ± 31.1 in invasive-PRL specimens, and 18/25 and 197.1 ± 46.6 in non-invasive specimens (x2 = 10.11, p = 0.001). A similar trend was also observed for p21 and p27 protein levels in PRL specimens through western-blot (P < 0.01, respectively). The Ki-67 index was much higher in invasive specimens than in non-invasive specimens (x2 = 10.10, p = 0.001). Average 33 CpG sites per sample were analyzed by using MALDI-TOF Mass array, and 7/33 CpG sites methylation levels of p27 were higher than 50%. There existed significant differences in 4 CpG sites between invasive specimens and non-invasive specimens (p < 0.01). We found that D2 receptor was closely correlated with p21 levels (P < 0.05, r = 0.567) and p27 levels (P < 0.05, r = 0.591). In PRL, the deficiency in p21 and p27 contributed to the tumor proliferation and migration and Cdk inhibitors may be used as a new therapeutic approach.

Entities:  

Keywords:  Invasion; Methylation; P21Waf1/Cip1; P27Kip1; Prolactinomas

Mesh:

Substances:

Year:  2017        PMID: 29230669     DOI: 10.1007/s11060-017-2683-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  49 in total

1.  Dopamine D(4) and D(2L) Receptor Stimulation of the Mitogen-Activated Protein Kinase Pathway Is Dependent on trans-Activation of the Platelet-Derived Growth Factor Receptor.

Authors:  J N Oak; N Lavine; H H Van Tol
Journal:  Mol Pharmacol       Date:  2001-07       Impact factor: 4.436

2.  Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression.

Authors:  I Pellegrini-Bouiller; I Morange-Ramos; A Barlier; G Gunz; D Figarella-Branger; C Cortet-Rudelli; F Grisoli; P Jaquet; A Enjalbert
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

3.  Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.

Authors:  E Delgrange; G Sassolas; G Perrin; M Jan; J Trouillas
Journal:  Acta Neurochir (Wien)       Date:  2005-03-14       Impact factor: 2.216

4.  The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene.

Authors:  S D Patel; A C Tran; Y Ge; M Moskalenko; L Tsui; G Banik; W Tom; M Scott; L Chen; M Van Roey; M Rivkin; M Mendez; J Gyuris; J G McArthur
Journal:  Mol Ther       Date:  2000-08       Impact factor: 11.454

Review 5.  Regulation of the cdk inhibitor p27 and its deregulation in cancer.

Authors:  J Slingerland; M Pagano
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

Review 6.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

7.  G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors.

Authors:  E Y Choi; D Jeong; K W Park; J H Baik
Journal:  Biochem Biophys Res Commun       Date:  1999-03-05       Impact factor: 3.575

8.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

9.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

10.  Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal.

Authors:  F Tortosa; S M Webb
Journal:  Neurologia       Date:  2015-08-20       Impact factor: 3.109

View more
  2 in total

Review 1.  Epigenetic Regulation of p21cip1/waf1 in Human Cancer.

Authors:  Matthias Ocker; Samar Al Bitar; Ana Carolina Monteiro; Hala Gali-Muhtasib; Regine Schneider-Stock
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

Review 2.  p21 in Cancer Research.

Authors:  Bahar Shamloo; Sinem Usluer
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.